• Home
• News
• About Us
• Contact

Search

Tag Cloud

anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defense Bio-Rescue Dengue fever Botulinum toxin antiviral molecular diagnostics Infectious disease

Subscribe to our newsletter

RSS Feed

Harvard study questions citizens' preparedness for anthrax attack
by Nick Rees on February 22, 2010

A recent study by researchers at the Harvard School of Public Health found that 89 percent of Americans, in the event of a significant anthrax bioattack, would follow public health recommendations in obtaining antibiotics.

Nanoviricides teams up with UC - Berkeley professor to test dengue virus drug candidates
by Nick Rees on February 17, 2010

A research and development agreement has been signed between NanoViricides, Inc., and the laboratory of Dr. Eva Harris at the University of California - Berkeley to evaluate the effectiveness of Nanoviricides drug candidates against dengue viruses.

Scott Habig joins Human Genome Sciences
by Nick Rees on February 3, 2010

Scott Habig has joined Human Genome Sciences, Inc., as vice president of sales.

Study published by Soligenix on characteristics of ricin A chain
by Nick Rees on December 29, 2009

Soligenix, Inc., has announced the publication of an article that details the characteristics of several immunodominant regions of ricin A chain - the antigenic component of Rivax - in the January 2010 edition of Infection and Immunity.

Positive results announced for Restanza in treatment of inhaled tularemia
by Ted Purlain on December 17, 2009

Positive top-line results have been announced by Advanced Life Sciences Holdings, Inc., for its once-a-day, oral antibiotic Restanza to treat inhaled lethal doses of tularemia.

Scientists Announce Possible Treatment for Deadly Virus
by Pat Dulnier on November 11, 2009

A team of Australian and U.S. scientists believe they have found an antibody that could protect humans from the deadly Hendra virus, Australia's Northern Miner reported yesterday.

University of Illinois to develop antibiotics against potential bioterrorism agents
by Ted Purlain on November 11, 2009

Researchers at the University of Illinois at Chicago have received a $4 million federal grant to develop new antibiotics to treat anthrax, tularemia and plague, the university announced Nov. 10.

FDA to discuss experimental drug’s effectiveness against anthrax
by Mary J. Lewis on October 26, 2009

A Human Genome Sciences Inc. drug worked better than a placebo but similar to antibiotics for treating anthrax exposure in animal studies, U.S. drug reviewers said in a summary released Oct. 23.

Emergent BioSolutions establishes office in Germany
by Paul Tinder on August 23, 2005

GAITHERSBURG, Md. — Emergent BioSolutions on Aug. 23, 2005, announced the opening of an office in Munich, Germany, dedicated to the expansion of markets throughout Europe and Asia.

Emergent BioSolutions appoints Ronald Richard to board of directors
by Ted Purlain on January 26, 2005

GAITHERSBURG, Md. — Emergent BioSolutions Inc. announced the appointment of Ronald Richard to its six-person board of directors.